A 2020 meta-analysis of 52 studies reported a significantly lower overall survival (OS) (HR 1.23; 95 % CI) in BRAF-mutated compared to wild-type melanoma,8 like the melanoma of our patient. The gene discussed is BRAF; the disease is melanoma.